THE FUTURE OF LAUNCH

The Future of U.S. Launch: Rewriting the Playbook

From U.S. Progress Point: At IQVIA, we’ve refined our take on the modern launch, and carefully considered what needs to change to achieve commercial success in a pressurized environment.

Latest On Launch

Launch Excellence, U.S. Edition: The Rewrite of the Business Launch

Today, a successful launch is no longer defined by just dollars — it’s defined by the number of patients reached, acquired, and retained. To reflect this new reality, we’ve refined our take on the modern launch, and carefully considered what needs to change to achieve commercial success in a pressurized environment.

In this paper, IQVIA experts discuss the clear need for a rewrite of the modern launch playbook.

WHITE PAPER
The NTB Forecast: Accuracy and Agility for a Modern Market
Discover the IQVIA NTB Forecast White Paper 2024, which introduces a groundbreaking methodology for pharmaceutical forecasting focused on new patient acquisition. Learn how the NTB Forecast achieves over 90% accuracy, transforming launch planning and strategic decision-making in the dynamic pharmaceutical market.
Latest On Launch
IQVIA Monthly Launch Tracker
What products are leading the launch pack? Is the therapy area mix changing? What key markets are bucking trends and creating a new normal? Tap into the IQVIA Monthly Launch Tracker for this and more. Data updated through July 2024.

U.S. Launch Excellence: A Three-Part Webinar Series

The U.S. launch environment is more pressurized than ever before. The convergence of legislative requirements, payer expectations of price and evidence, and meeting patients’ needs means an aligned launch strategy is mission critical. Each installment of this three-part webinar series will focus on a key phase of launch excellence.

U.S. Launch Landscape
A real-time conversation on launch
In this and future issues, we will rigorously investigate the past and present in an effort to understand the future.
What is the definition of launch success?
Is there an optimal way to engage and educate providers on new products?
What is the impact of patient behavior, access, and affordability?
How much can a launch-naïve company rely on historical norms versus brave new pathways?

LAUNCH EXCELLENCE PODCAST SERIES

Select Podcast Episodes

Elyse Muñoz, Director of U.S. Research and Insights, joins podcast series host Sarah Rickwood, Vice President of EMEA Thought Leadership, to discuss the new rules for launch excellence in the U.S., the most important market for global innovative medicines success.

 

 

 

 

 
U.S. Progress Point Subscribers' Circle: First-looks, exclusive content, and more.
Contact Us